Regenxbio (NASDAQ: RGNX) net income
Regenxbio reported a net loss of $193.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $227.1m. Earnings per share were −$3.76.
Regenxbio's best year of the last 10 was fiscal 2021. It reported a loss in 8 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$193.9m | — | −113.8% | −$3.76 |
| 2024 | −$227.1m | — | −272.5% | −$4.59 |
| 2023 | −$263.5m | — | −292.0% | −$6.02 |
| 2022 | −$280.3m | −319.3% | −248.7% | −$6.50 |
| 2021 | $127.8m | — | 27.2% | $3.01 |
| 2020 | −$111.3m | — | −72.0% | −$2.98 |
| 2019 | −$94.7m | −194.8% | −268.9% | −$2.58 |
| 2018 | $99.9m | — | 45.7% | $2.99 |
| 2017 | −$73.2m | — | −704.0% | −$2.45 |
| 2016 | −$63.0m | — | −1,372.1% | −$2.38 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Regenxbio net income compared with its sector
By net income for its latest fiscal year, Regenxbio ranks 406th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Regenxbio, −113.8%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 404th | Allogene Therapeutics | −$190.9m | −7,341.8% |
| 405th | Sutro Biopharma | −$191.1m | −186.5% |
| 406th | Regenxbio | −$193.9m | −113.8% |
| 407th | Karyopharm Therapeutics | −$196.0m | −134.2% |
| 408th | Rhythm Pharmaceuticals | −$196.5m | −103.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Regenxbio
- How much did Regenxbio earn in fiscal 2025?
- Regenxbio reported a net loss of $193.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $227.1m.
- What are the earnings per share of Regenxbio?
- They were −$3.76 in fiscal 2025, compared with −$4.59 in fiscal 2024.
- What was the most profitable year for Regenxbio?
- Of its last 10 fiscal years, fiscal 2021, with $127.8m.
- Where does Regenxbio rank in its sector by net income?
- It ranks 406th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Regenxbio come from?
- From the annual report (Form 10-K) that Regenxbio files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Regenxbio files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Regenxbio: the Regenxbio page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.